Evidence map›Paper›PMID 30572767›Full record

ArticleCancer biology & therapy2019

Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies.

Zhenlong Ye, Yongmei Ding, Zhuo Chen, Zhong Li, Shuo Ma, Zenghui Xu, Liang Cheng, Xinyue Wang, Xiaoxia Zhang, Na Ding and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. SimultaneousAnnals of translational medicine · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Zhenlong Yea Shanghai Baize Medical Laboratory , Shanghai Engineering Research Center for Cell Therapy , Shanghai , China.
Yongmei Dingb Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital , The Second Military Medical University , Shanghai , China.
Zhuo Chena Shanghai Baize Medical Laboratory , Shanghai Engineering Research Center for Cell Therapy , Shanghai , China.
Zhong Lia Shanghai Baize Medical Laboratory , Shanghai Engineering Research Center for Cell Therapy , Shanghai , China.
Shuo Maa Shanghai Baize Medical Laboratory , Shanghai Engineering Research Center for Cell Therapy , Shanghai , China.
Zenghui Xua Shanghai Baize Medical Laboratory , Shanghai Engineering Research Center for Cell Therapy , Shanghai , China.
Liang Chenga Shanghai Baize Medical Laboratory , Shanghai Engineering Research Center for Cell Therapy , Shanghai , China.
Xinyue Wanga Shanghai Baize Medical Laboratory , Shanghai Engineering Research Center for Cell Therapy , Shanghai , China.
Xiaoxia Zhanga Shanghai Baize Medical Laboratory , Shanghai Engineering Research Center for Cell Therapy , Shanghai , China.
Na Dinga Shanghai Baize Medical Laboratory , Shanghai Engineering Research Center for Cell Therapy , Shanghai , China.
Qian Zhangb Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital , The Second Military Medical University , Shanghai , China.
Qijun Qiana Shanghai Baize Medical Laboratory , Shanghai Engineering Research Center for Cell Therapy , Shanghai , China.
Shanghai Cell Therapy Research Institute · CNEastern Hepatobiliary Surgery Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating tumor cells (CTCs) have been exclusively studied and served to assess the clinical outcomes of treatments and progression of cancer. Most CTC data have mainly been derived from distinct cohorts or selected tumor types. In the present study, a total of 594 blood samples from 479 cases with 19 different carcinomas and 30 healthy samples were collected and analyzed by Subtraction enrichment method combined with immunostaining-fluorescence in situ hybridization (iFISH). Non-hematopoietic cells with aneuploid chromosome 8 (more than 2 copies) were regarded as positive CTCs. The results showed that none of CTCs was found in all 30 healthy samples. The overall positive rate of CTCs was 89.0% in diagnosed cancer patients (ranging from 75.0% to 100.0%). Average number of 11, 5, 8 and 4 CTCs per 7.5 mL was observed in lung cancer, liver cancer, renal cancer and colorectal cancer, respectively. Among 19 different carcinomas, the total number of CTCs, tetraploid chromosome 8, polyploid chromosome 8, CTM (Circulating tumor microemboli) and large CTCs in patients with stage Ⅲ and Ⅳ were statistically higher than patients with stage Ⅰ and Ⅱ (P < 0.05). Furthermore, EpCAM expression was more frequently found in most CTCs than vimentin expression, confirming that these CTCs were of epithelial origin. In addition, small and large CTCs were also classified, and the expression of vimentin was mostly observed in small CTCs and CTM. Our results revealed that there are higher numbers of CTCs, tetraploid, polyploid and large CTCs in patients with stage Ⅲ and Ⅳ, indicating that the quantification of chromosome ploidy performed by SE-iFISH for CTCs might be a useful tool to predict and evaluate therapeutic efficacy as well as to monitoring disease progression.

Indexed as

Biomarkers, TumorCase-Control StudiesCohort StudiesEpithelial Cell Adhesion MoleculeFollow-Up StudiesHumansIn Situ Hybridization, FluorescenceNeoplasmsNeoplastic Cells, CirculatingPrognosisVimentinBiomarkers, TumorEPCAM protein, humanEpithelial Cell Adhesion MoleculeVimentinVIM protein, humanCirculating tumor cellsCTCsEpCAMiFISHVimentin

Identifiers

PMID30572767
PMCPMC6422472
OpenAlexW2906385796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.